Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib

• Published in: Frontiers in oncology Vol. 13; p. 1104910
• Main Authors: Zhai, Xiaoqian, Wang, Ting, Lin, Yiyun, Zhang, Jiabi, Wang, Yuqing, Wang, Weiya, Zhou, Qinghua, Zhu, Daxing
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29.03.2023
• Subjects: complete pathologic response; crizotinib; INTS10-ALK and EML4-ALK; lung cancer; neoadjuvant; Oncology; stage IIIB-N3; lung cancer; crizotinib; neoadjuvant; stage IIIB-N3; complete pathologic response; case report; INTS10-ALK and EML4-ALK

Although anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have impressive response in advanced lung adenocarcinoma with anaplastic lymphoma kinase (ALK) fusion, no guidelines point to the potential benefits of neoadjuvant ALK-TKIs for N3 unresectable locally advanced lung cancer. Cur...